Medherant announces positive Phase I results for its first transdermal drug delivery patch
Coventry, UK, 5th November 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI Patch®. The ...
Innovate UK Awards Medherant a Medicines Manufacturing Grant
New funding to support manufacture of transdermal patches for clinical trials Coventry, UK, 3rd October 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medicines M...

Medherant nominated for two CPhI Pharma Awards
Medherant has been shortlisted for the CPhI Pharma Awards in both the Formulation and Drug Delivery Devices categories for its TEPI Patch® technology. This year marks the 15th anniversary of the CPhI Pharma Awards which are among the ...

Patch up the pain: A case study in transdermal drug delivery
Dr Vasiliki Nikolaou and Prof David Haddleton discuss trandsdermal patches in MedNous Transdermal drug delivery systems have been used in different forms since ancient times. The first patch reached the market in 1981 for the treatment of motion s...
Breaking Through – Medherant’s Professor David Haddleton and Dr Vasiliki Nikolaou discuss transdermal drug delivery systems in Innovations in Pharmaceutical Technology
There are many problems linked to oral drug administration including first pass metabolism, gastrointestinal tract damage and low levels of drug reaching the target site. Trying to overcome these is an important area of research across the pharmaceut...